Muscarinic M3 receptors exist in the gastrointestinal wall in @entity1 and the muscarinic M3 agonist @entity15246 (Evoxac) is a candidate therapeutic agent for the treatment of @entity2133 in Sj  gren's syndrome. However, M3 receptor agonists are not known to show efficacy for diseases associated with @entity344 . Herein the effects are reported of @entity15246 on @entity356 in two @entity1 with @entity1066 . The @entity1 both received long-term proton pump inhibitor therapy for 6 months, but their symptoms persisted. Then cevimeline was administered orally for 8 weeks at 30 mg three times daily (90 mg/day) and their @entity2210 symptoms improved. Electrogastrography was performed to examine @entity356 before and after administration of the M3 agonist. The fasting or nocturnal wave rate was significantly increased after administration compared with before administration, but no significant postprandial changes were seen. No adverse effects of cevimeline were observed. This drug might be a candidate therapeutic agent for @entity1066 . Because its postprandial effects on @entity344 are unclear, a dose-finding clinical study should be performed in the future.

Effect of a muscarinic M3 receptor agonist on XXXX .

@entity1 :: ('9606', 'Species') :: ['humans', 'patients'] @entity2133 :: ('MESH:D014987', 'Disease') :: ['xerostomia'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['non-ulcer dyspepsia'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal motility', 'abnormal gastrointestinal motility'] @entity2210 :: ('MESH:D004415', 'Disease') :: ['dyspepsia'] @entity15246 :: ('MESH:C059240', 'Chemical') :: ['cevimeline hydrochloride', 'cevimeline'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric motility']
@entity356 :: (MESH:D013274,Disease) :: ['gastric motility']
